āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™

TCDA Technical Analysis 🧙

253
Tricida Inc is a late-stage pharmaceutical company. It is focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

If you understand the idea,ðŸŽŊ press a thumb up! 👍 Have a question? Don't be shy to ask! ðŸĪ“ Interested to study how to analyze charts, follow me!

āļ„āļģāļˆāļģāļāļąāļ”āļŠāļīāļ—āļ˜āļīāđŒāļ„āļ§āļēāļĄāļĢāļąāļšāļœāļīāļ”āļŠāļ­āļš

āļ‚āđ‰āļ­āļĄāļđāļĨāđāļĨāļ°āļšāļ—āļ„āļ§āļēāļĄāđ„āļĄāđˆāđ„āļ”āđ‰āļĄāļĩāļ§āļąāļ•āļ–āļļāļ›āļĢāļ°āļŠāļ‡āļ„āđŒāđ€āļžāļ·āđˆāļ­āļāđˆāļ­āđƒāļŦāđ‰āđ€āļāļīāļ”āļāļīāļˆāļāļĢāļĢāļĄāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™, āļāļēāļĢāļĨāļ‡āļ—āļļāļ™, āļāļēāļĢāļ‹āļ·āđ‰āļ­āļ‚āļēāļĒ, āļ‚āđ‰āļ­āđ€āļŠāļ™āļ­āđāļ™āļ° āļŦāļĢāļ·āļ­āļ„āļģāđāļ™āļ°āļ™āļģāļ›āļĢāļ°āđ€āļ āļ—āļ­āļ·āđˆāļ™ āđ† āļ—āļĩāđˆāđƒāļŦāđ‰āļŦāļĢāļ·āļ­āļĢāļąāļšāļĢāļ­āļ‡āđ‚āļ”āļĒ TradingView āļ­āđˆāļēāļ™āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ—āļĩāđˆ āļ‚āđ‰āļ­āļāļģāļŦāļ™āļ”āļāļēāļĢāđƒāļŠāđ‰āļ‡āļēāļ™